Skip to main content
PLUR
NASDAQ Life Sciences

Pluri Inc. Reports Less Than 3 Months Cash Runway, Faces Imminent $27.4M EIB Loan Maturity

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$3.4
Mkt Cap
$34.173M
52W Low
$2.82
52W High
$6.1
Market data snapshot near publication time

summarizeSummary

Pluri Inc. is facing an acute liquidity crisis with less than three months of cash runway and an imminent $27.4 million EIB loan maturity, raising significant going concern doubts.


check_boxKey Events

  • Going Concern Warning Issued

    Management estimates the company has sufficient resources for less than three months of operating obligations, raising substantial doubt about its ability to continue as a going concern.

  • Imminent $27.4M EIB Loan Maturity

    A $27.4 million loan from the European Investment Bank (EIB) is due on June 1, 2026. Discussions for restructuring are ongoing, but there is no assurance of a favorable outcome.

  • Increased Net Losses and Cash Burn

    Net loss for the nine-month period ended March 31, 2026, increased to $19.18 million, up from $15.48 million in the prior year. Net cash used in operating activities also increased to $15.15 million.

  • Recent Capital Injections Insufficient

    The company secured $5 million from its Chairman in two private placements (December 2025 and March/April 2026) and sold 23,300 shares for $43,000 under its ATM program, but these funds do not resolve the immediate liquidity challenges.


auto_awesomeAnalysis

Pluri Inc. has disclosed a critical liquidity crisis, with management estimating less than three months of cash runway from the filing date. This raises substantial doubt about the company's ability to continue as a going concern. Compounding this, a significant $27.4 million loan from the European Investment Bank (EIB) is due on June 1, 2026, with ongoing restructuring discussions offering no certainty of a resolution. Despite recent capital injections totaling $5 million from its Chairman and minor ATM sales, these funds are insufficient to offset the company's increased net losses and cash burn from operations, indicating a severe and immediate financial challenge.

At the time of this filing, PLUR was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.2M. The 52-week trading range was $2.82 to $6.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PLUR - Latest Insights

PLUR
May 14, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
9
PLUR
May 01, 2026, 7:57 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
PLUR
Mar 27, 2026, 6:33 AM EDT
Filing Type: 8-K
Importance Score:
9
PLUR
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
PLUR
Mar 02, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
8
PLUR
Feb 12, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
10
PLUR
Jan 22, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
PLUR
Jan 05, 2026, 7:42 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9